Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 7
Submit an article Journal homepage
3,646
Views
194
CrossRef citations to date
0
Altmetric
Special Focus: Vaccine Adjuvants - Review

The use of Toll-like receptor 7/8 agonists as vaccine adjuvants

John P Vasilakos Drug Delivery Systems Division, 3M Center, Building 260-4S-13, St Paul, MN 55144, USA. [email protected]; Drug Delivery Systems Division, 3M Center, Building 260-4S-13, St Paul, MN 55144, USA. [email protected]
&
Mark A Tomai MTS and Vaccine Business Development, 3M Drug Delivery Systems Division, 3M Center, Building 275-03-E-10, St Paul, MN 55144, USA; MTS and Vaccine Business Development, 3M Drug Delivery Systems Division, 3M Center, Building 275-03-E-10, St Paul, MN 55144, USA
Pages 809-819 | Published online: 09 Jan 2014

References

  • Singh M, Ugozzoli M, Kazzaz J et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24(10), 1680–1686 (2006).
  • Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277–296 (1995).
  • Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 33(4), 492–503 (2010).
  • Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S et al. Combination adjuvants: the next generation of adjuvants? Expert Rev. Vaccines 10(1), 95–107 (2011).
  • Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89–97 (2000).
  • Medzhitov R, Janeway C Jr. Innate immunity. N. Engl. J. Med. 343(5), 338–344 (2000).
  • Medzhitov R, Janeway CA Jr. An ancient system of host defense. Curr. Opin. Immunol. 10(1), 12–15 (1998).
  • Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, Hunninghake GW. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J. Immunol. 176(3), 1733–1740 (2006).
  • Hewson CA, Jardine A, Edwards MR, Laza-Stanca V, Johnston SL. Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. J. Virol. 79(19), 12273–12279 (2005).
  • Matsumoto M, Funami K, Tanabe M et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 171(6), 3154–3162 (2003).
  • Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun. 293(5), 1364–1369 (2002).
  • Ueta M, Hamuro J, Kiyono H, Kinoshita S. Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines. Biochem. Biophys. Res. Commun. 331(1), 285–294 (2005).
  • Poulin LF, Salio M, Griessinger E et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells. J. Exp. Med. 207(6), 1261–1271 (2010).
  • Medzhitov R, Janeway CA Jr. On the semantics of immune recognition. Res. Immunol. 147(4), 208–214 (1996).
  • Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2(8), 675–680 (2001).
  • Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5(10), 987–995 (2004).
  • Janeway CA Jr, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin. Immunol. 10(5), 349–350 (1998).
  • Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86(6), 973–983 (1996).
  • Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley’s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med. Scand. Suppl. 276, 1–103 (1953).
  • Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471–484 (2006).
  • Schreibelt G, Benitez-Ribas D, Schuurhuis D et al. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 116(4), 564–574 (2010).
  • Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9(10), 741–747 (2009).
  • Querec T, Bennouna S, Alkan S et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203(2), 413–424 (2006).
  • Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv. Drug Deliv. Rev. 60(7), 813–823 (2008).
  • Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 36(12), 3256–3267 (2006).
  • Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196–200 (2002).
  • Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3(6), 499 (2002).
  • Ahonen CL, Gibson SJ, Smith RM et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell. Immunol. 197(1), 62–72 (1999).
  • Gibson SJ, Lindh JM, Riter TR et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 218(1–2), 74–86 (2002).
  • Kaisho T, Akira S. Regulation of dendritic cell function through Toll-like receptors. Curr. Mol. Med. 3(4), 373–385 (2003).
  • Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 21(2), 69–87 (2008).
  • Wysocka M, Newton S, Benoit BM et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-γ enhances production of interleukin-12. Clin. Lymphoma Myeloma 7(8), 524–534 (2007).
  • Burns RP Jr, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans’ cells. Clin. Immunol. 94(1), 13–23 (2000).
  • Fogel M, Long JA, Thompson PJ, Upham JW. Dendritic cell maturation and IL-12 synthesis induced by the synthetic immune-response modifier S-28463. J. Leukoc. Biol. 72(5), 932–938 (2002).
  • Loré K, Betts MR, Brenchley JM et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol. 171(8), 4320–4328 (2003).
  • Ramakrishna V, Vasilakos JP, Tario JD Jr, Berger MA, Wallace PK, Keler T. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J. Transl. Med. 5, 5 (2007).
  • Wagner TL, Ahonen CL, Couture AM et al. Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol. 191(1), 10–19 (1999).
  • Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int. J. Infect. Dis. 14(9), e781–e787 (2010).
  • Du J, Wu Z, Ren S et al. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine 28(38), 6273–6281 (2010).
  • Durand V, Wong SY, Tough DF, Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-α/β. Immunol. Cell Biol. 82(6), 596–602 (2004).
  • Ma R, Du JL, Huang J, Wu CY. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem. Biophys. Res. Commun. 361(2), 537–542 (2007).
  • Otero M, Calarota SA, Felber B et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 22(13–14), 1782–1790 (2004).
  • Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22(13–14), 1799–1809 (2004).
  • Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell. Immunol. 203(1), 55–65 (2000).
  • Vasilakos JP, Smith RM, Gibson SJ et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol. 204(1), 64–74 (2000).
  • Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin. Vaccine Immunol. 17(12), 1850–1858 (2010).
  • Wille-Reece U, Flynn BJ, Loré K et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA 102(42), 15190–15194 (2005).
  • Zhang WW, Matlashewski G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun. 76(8), 3777–3783 (2008).
  • Chang BA, Cross JL, Najar HM, Dutz JP. Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 27(42), 5791–5799 (2009).
  • Baldwin SL, Bertholet S, Kahn M et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 27(23), 3063–3071 (2009).
  • Weldon WC, Zarnitsyn VG, Esser ES et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS ONE 7(7), e41501 (2012).
  • Adams S, Kozhaya L, Martiniuk F et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin. Cancer Res. 18(24), 6748–6757 (2012).
  • Narayan R, Nguyen H, Bentow JJ et al. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J. Invest. Dermatol. 132(1), 163–169 (2012).
  • Adams S, O’Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181(1), 776–784 (2008).
  • Ahonen CL, Doxsee CL, McGurran SM et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199(6), 775–784 (2004).
  • Caproni E, Tritto E, Cortese M et al. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J. Immunol. 188(7), 3088–3098 (2012).
  • Cheng C, Jain P, Bettahi I, Pal S, Tifrea D, de la Maza LM. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine 29(38), 6641–6649 (2011).
  • Lumsden JM, Nurmukhambetova S, Klein JH et al. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 30(22), 3311–3319 (2012).
  • Oh JZ, Kedl RM. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 185(8), 4602–4608 (2010).
  • Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 115(10), 1949–1957 (2010).
  • Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848). Vaccine 23(45), 5263–5270 (2005).
  • Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol. 174(12), 7676–7683 (2005).
  • Zhao K, Wang H, Wu C. The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848. Vaccine 29(38), 6670–6678 (2011).
  • Soria I, Myhre P, Horton V et al. Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int. J. Clin. Pharmacol. Ther. 38(10), 476–481 (2000).
  • Ketloy C, Engering A, Srichairatanakul U et al. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet. Immunol. Immunopathol. 125(1–2), 18–30 (2008).
  • Watanabe J, Miyazaki Y, Zimmerman GA, Albertine KH, McIntyre TM. Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity. J. Biol. Chem. 278(43), 42361–42368 (2003).
  • Kastenmüller K, Wille-Reece U, Lindsay RW et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 121(5), 1782–1796 (2011).
  • Tomai MA, Vasilakos JP. TLR7/8 agonists. In: Novel Immunologic Adjuvants. Rappuoli R, De Gregorio E (Eds). Future Medicine Ltd, London, UK, 81–92 (2011).
  • Shukla NM, Lewis TC, Day TP et al. Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound Toll-like receptor-7 agonistic imidazoquinolines. Bioorg. Med. Chem. Lett. 21(11), 3232–3236 (2011).
  • Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543–547 (2011).
  • Lehner M, Stilper A, Morhart P, Holter W. Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-γ). J. Leukoc. Biol. 83(4), 883–893 (2008).
  • Mäkelä SM, Osterlund P, Julkunen I. TLR ligands induce synergistic interferon-β and interferon-λ1 gene expression in human monocyte-derived dendritic cells. Mol. Immunol. 48(4), 505–515 (2011).
  • Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769–776 (2005).
  • Pufnock JS, Cigal M, Rolczynski LS et al. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood 117(24), 6542–6551 (2011).
  • Sanchez PJ, McWilliams JA, Haluszczak C, Yagita H, Kedl RM. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J. Immunol. 178(3), 1564–1572 (2007).
  • Xu S, Koldovsky U, Xu M et al. High-avidity antitumor T-cell generation by Toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production. Surgery 140(2), 170–178 (2006).
  • Morse MA, Chapman R, Powderly J et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 17(14), 4844–4853 (2011).
  • Shukla NM, Salunke DB, Balakrishna R, Mutz CA, Malladi SS, David SA. Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer. PLoS ONE 7(8), e43612 (2012).
  • Smirnov D, Schmidt JJ, Capecchi JT, Wightman PD. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29(33), 5434–5442 (2011).
  • Tomai MA, Vasilakos JP. TLR-7 and -8 agonists as vaccine adjuvants. Expert Rev. Vaccines 10(4), 405–407 (2011).
  • Tomai MA, Vasilakos JP. TLR agonists as vaccine adjuvants. In: Innovation in Vaccinology: From Design, Through to Delivery and Testing. Baschieri S (Ed.). Springer Heidelberg, Germany, 205–228 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.